FMP
NASDAQ
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
2.51 USD
-0.29 (-11.55%)
Valuation Date:
Sep 6, 2024 4:00 PM
Share Price on Valuation Date
$2.51
Stock Beta
0.637
Shares Outstanding
1074196